The Jerusalem Post By ZACHARY KEYSER AUGUST 11, 2020
The initial results from an Israeli in vivo study testing the benefits of using cannabis terpenes to treat inflammatory infections, such as COVID-19, have been quite promising.
The fledgling study, being carried out by Israeli cannabis research and development firms Eybna and CannaSoul, is centered around examining the effectiveness of the use of a unique cannabis terpene formulation - NT-VRL - with respect to treating inflammatory conditions such as cytokine storm syndrome, which commonly occurs in serious cases of COVID-19.
Cytokine storms occur when the body overproduces immune cells and their activating compounds (cytokines), causing dangerously high blood pressure, lung damage, respiratory distress syndrome and organ failure. This is a common occurrence in some patients where the immune system's response to COVID-19 is extreme and goes into overdrive to fight the virus. Accumulating evidence shows that many COVID-19 patients die because of the increase in the production of the inflammatory cytokine molecules, rather than the virus itself.
“The preliminary results were highly positive. Demonstrating significant anti-inflammatory activity of terpenes and breaking the perception that terpenes are just flavorings and fragrances compounds with a placebo effect," said Eybna Co-founder and CEO Nadav Eyal.
More:
https://www.jpost.com/health-science/israeli-study-finds-efficacy-in-using-cannabis-terpenes-to-treat-covid-19-638198
